Published Paper Details:

Transdermal patches are a non-invasive drug delivery system designed to deliver medications through the skin directly into the bloodstream, offering an alternative to oral and injectable routes. This method provides sustained and controlled release of drugs, potentially enhancing therapeutic efficacy and patient compliance. This paper reviews the mechanisms of transdermal delivery, the types of drugs suitable for this route, the design and development of transdermal patches, and the advantages and challenges associated with their use. Current advancements in technology and materials, as well as future directions for research and development, are also discussed. Purpose: Transdermal patches deliver medication more directly to the bloodstream by by passing processing in the liver. Transdermal patches deliver medication over a longer period of time than traditional systems, which can be easier on patients who experience extreme side effects. Method: The process of solvent casting can be utilized for manufacturing Transdermal patch utilizing polymers such as HPMC , PVPK-30 and Eudragit L-100. The ratio of chloroform to mthanol employed as a solvent was 5:5. The mechanical stirrer's speed was 500 rpm. Result: Among the various formulations evaluated, batch F4 emerged as the most suitable choice for preparing Etodolac Transdermal patch. This particular formulation contains 50% (w/w) Pvpk-30 and 17% (w/w) PEG 400, which have proven to be effective in achieving the desired outcomes. The F-4 formulation exhibited good organoleptic properties and a folding endurance of 5, indicating its durability during handling. In-vitro dissolution studies demonstrated a rapid drug release rate of 97.66% within 8 hr, while the patch disintegrated in just 8 hr. These findings highlight the significant potential of utilizing polymers like Hpmc, Pvpk-30 and Eudragit L-100 for the development of highly effective and patient-friendly Transdermal drug delivery systems. Conclusion: The research indicates that utilizing the solvent casting process with HPMC , PVPK-30 and Eudragit L-100 to create Transdermal patch containing Etodolac is an acceptable method.